These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 39192322)

  • 61. Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.
    Toss MS; Miligy IM; Gorringe KL; McCaffrey L; AlKawaz A; Abidi A; Ellis IO; Green AR; Rakha EA
    Mod Pathol; 2019 May; 32(5):639-649. PubMed ID: 30429518
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A Case Report of
    Lee M; Lee J; Lee A; Kang J
    Int J Surg Pathol; 2023 Aug; 31(5):801-804. PubMed ID: 36437641
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Underestimation of invasive lesions in patients with ductal carcinoma in situ of the breast diagnosed by ultrasound-guided biopsy: a comparison between patients with and without HER2/neu overexpression.
    Chang WC; Hsu HH; Yu JC; Ko KH; Peng YJ; Tung HJ; Chang TH; Hsu GC
    Eur J Radiol; 2014 Jun; 83(6):935-941. PubMed ID: 24666513
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less.
    Toss A; Palazzo J; Berger A; Guiles F; Sendecki JA; Simone N; Anne R; Avery T; Jaslow R; Lazar M; Tsangaris T; Cristofanilli M
    Breast; 2016 Oct; 29():223-30. PubMed ID: 27506636
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial.
    Thorat MA; Levey PM; Jones JL; Pinder SE; Bundred NJ; Fentiman IS; Cuzick J
    Clin Cancer Res; 2021 Oct; 27(19):5317-5324. PubMed ID: 34380636
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Expression of CD151/Tspan24 and integrin alpha 3 complex in aid of prognostication of HER2-negative high-grade ductal carcinoma in situ.
    Romanska HM; Potemski P; Kusinska R; Kopczynski J; Sadej R; Kordek R
    Int J Clin Exp Pathol; 2015; 8(8):9471-8. PubMed ID: 26464707
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients.
    Koh VC; Lim JC; Thike AA; Cheok PY; Thu MM; Tan VK; Tan BK; Ong KW; Ho GH; Tan WJ; Tan Y; Salahuddin AS; Busmanis I; Chong AP; Iqbal J; Thilagaratnam S; Wong JS; Tan PH
    Breast Cancer Res Treat; 2015 Jul; 152(2):293-304. PubMed ID: 26077641
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Qualitative Radiogenomics: Association Between BI-RADS Calcification Descriptors and Recurrence Risk as Assessed by the Oncotype DX Ductal Carcinoma In Situ Score.
    Woodard GA; Price ER
    AJR Am J Roentgenol; 2019 Apr; 212(4):919-924. PubMed ID: 30714832
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion.
    Wan ZB; Gao HY; Wei L; Zhang AQ; Zhang JY; Wang Y; Wang DD; Zhang Y
    Medicine (Baltimore); 2018 Nov; 97(44):e13055. PubMed ID: 30383678
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Does molecular biology play any role in ductal carcinoma in situ?].
    Sakr RA
    Gynecol Obstet Fertil; 2013 Jan; 41(1):45-53. PubMed ID: 23286959
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion.
    Fang Y; Wu J; Wang W; Fei X; Zong Y; Chen X; Huang O; He J; Chen W; Li Y; Shen K; Zhu L
    Oncotarget; 2016 Sep; 7(39):64182-64190. PubMed ID: 27577080
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
    Baqai T; Shousha S
    Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Discordant HER2 immunohistochemical expression and gene amplification in ductal carcinoma in situ - evaluating HER2 in synchronous in-situ and invasive carcinoma.
    Hui Y; Lu S; Wang H; Resnick MB; Wang Y
    Histopathology; 2019 Jan; 74(2):358-362. PubMed ID: 30117181
    [No Abstract]   [Full Text] [Related]  

  • 75. The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease.
    Harada S; Mick R; Roses RE; Graves H; Niu H; Sharma A; Schueller JE; Nisenbaum H; Czerniecki BJ; Zhang PJ
    J Surg Oncol; 2011 Oct; 104(5):458-65. PubMed ID: 21557226
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence.
    Jirström K; Ringberg A; Fernö M; Anagnostaki L; Landberg G
    Br J Cancer; 2003 Nov; 89(10):1920-6. PubMed ID: 14612904
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
    Mardekian SK; Bombonati A; Palazzo JP
    Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
    [TBL] [Abstract][Full Text] [Related]  

  • 79. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy.
    Collins LC; Schnitt SJ
    Mod Pathol; 2005 May; 18(5):615-20. PubMed ID: 15696127
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.
    Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X
    PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.